



# IN THE CLAIMS

1-68. (canceled)


69. (original) A compound having the formula




wherein  $R_2$  and  $R_3$  are independently hydrogen, or a glycoside having the formula



where  $n=0$  to 8 and  $R_9$  is an alkyl, alkylene, monocationic alkylamine or polycationic alkylamine, where  $R$  is a lower alkylene, where  $R'$  is




where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,  $R_1$  is hydrogen or a pharmacologically active drug residue, and  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

70. (amended) The compound of Claim 69 wherein  $R_2$  is hydrogen and  $R_3$  is a glycoside having the formula



71. (amended) The compound of Claim 70 wherein  $R_3$  is a glycoside having the formula




where  $n=0$  to about 8.


72. (original) The compound of Claim 70 wherein  $R_9$  is a monocationic alkylamine or polycationic alkylamine.

73. (original) The compound of Claim 72 wherein the alkylamine is a quaternary amine.

74. (Amended) The compound of Claim 71 having the formula




75. (original) The compound of Claim 70 having the formula



76. (original) The compound of Claim 75 wherein  $R_9$  is a monocationic alkylamine or polycationic alkylamine.


77. (original) The compound of Claim 76 wherein the alkylamine is a quaternary amine.

78. (new) A pharmaceutical composition useful for the treatment of inflammatory disease or for reducing inflammation which composition comprises an inflammation reducing effective amount of a compound having the formula




where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,  $R$  is an alkylene having from 1 to about 6 carbon atoms a heteroalkylene containing carbon, nitrogen and oxygen atoms,  $R_1$  is hydrogen or a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, or aralkyl, and  $n=0$  to about 8, with the proviso that said compound contains at least one pharmacologically active drug residue or a pharmaceutically acceptable salt thereof.

79. (new) The composition of Claim 78 comprising a compound having the formula




and its pharmaceutically acceptable salt.

80. (new) A pharmaceutical composition useful for the treatment of infectious disease or for reducing infection which composition comprises an infection reducing effective amount of a compound having the formula




where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,  $R$  is an alkylene having from 1 to about 6 carbon atoms a heteroalkylene containing carbon, nitrogen and oxygen atoms,  $R_1$  is hydrogen or a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, or aralkyl, and  $n=0$  to about 8, with the proviso that said compound contains at least one pharmacologically active drug residue or a pharmaceutically acceptable salt thereof.

81. (new) The composition of Claim 80 comprising a compound having the formula



and its pharmaceutically acceptable salt.


82. (new) A pharmaceutical composition useful for the treatment of glaucoma or for reducing intraocular pressure which composition comprises a therapeutically effective amount of a compound having the formula



where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,  $R$  is an alkylene having from 1 to about 6 carbon atoms a heteroalkylene containing carbon, nitrogen and oxygen atoms,  $R_1$  is hydrogen or a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, or aralkyl, and  $n=0$  to about 8, with the proviso that said compound contains at least one pharmacologically active drug residue or a pharmaceutically acceptable salt thereof.




83. (new) The composition of Claim 82 comprising a compound having the formula




and its pharmaceutically acceptable salt.

84. (new) A pharmaceutical composition useful for administering therapeutic compositions ocularly for the treatment of systemic disorders, which composition comprises a therapeutically effective amount of a compound having the formula




where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,  $R$  is an alkylene having from 1 to about 6 carbon atoms a heteroalkylene containing carbon, nitrogen and oxygen atoms,  $R_1$  is hydrogen or a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, or aralkyl, and  $n=0$  to about 8, with the proviso that said compound contains at least one pharmacologically active drug residue or a pharmaceutically acceptable salt thereof.

85. (new) The composition of Claim 84 comprising a compound having the formula




and its pharmaceutically acceptable salt.

86. (new) A pharmaceutical composition useful for the treatment of an oncology disease or for reducing tumors which composition comprises a tumor reducing effective amount of a compound having the formula



where  $X = 0$  or  $1$ ,  $Y = 0$  or  $1$ ,  $R$  is an alkylene having from 1 to about 6 carbon atoms a heteroalkylene containing carbon, nitrogen and oxygen atoms,  $R_1$  is hydrogen or a pharmacologically active drug residue,  $R_4$ ,  $R_5$ , and  $R_6$  are independently hydrogen, alkyl, aryl, or aralkyl, and  $n=0$  to about 8, with the proviso that said compound contains at least one pharmacologically active drug residue or a pharmaceutically acceptable salt thereof.

87. (new) The composition of Claim 86 comprising a compound having the formula



and its pharmaceutically acceptable salt.